[MAYBANK] QoQ TTM Result on 30-Jun-2021 [#2]

Announcement Date
26-Aug-2021
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2021
Quarter
30-Jun-2021 [#2]
Profit Trend
QoQ- 14.96%
YoY- 5.45%
View:
Show?
TTM Result
31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 CAGR
Revenue 45,649,018 45,959,390 46,946,704 49,555,536 50,007,731 51,013,933 51,750,148 -8.02%
PBT 10,687,417 10,886,595 10,158,532 10,501,010 9,030,705 8,656,956 9,928,430 5.03%
Tax -2,707,197 -2,565,080 -2,318,674 -2,389,534 -1,925,635 -1,937,877 -2,282,427 12.06%
NP 7,980,220 8,321,515 7,839,858 8,111,476 7,105,070 6,719,079 7,646,003 2.89%
-
NP to SH 7,748,992 8,096,229 7,576,763 7,844,493 6,823,699 6,481,219 7,392,944 3.18%
-
Tax Rate 25.33% 23.56% 22.82% 22.76% 21.32% 22.39% 22.99% -
Total Cost 37,668,798 37,637,875 39,106,846 41,444,060 42,902,661 44,294,854 44,104,145 -9.98%
-
Net Worth 83,815,975 85,785,748 83,885,667 82,869,597 83,826,660 84,436,116 83,289,500 0.42%
Dividend
31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 CAGR
Div 6,784,472 6,784,472 7,549,914 9,067,498 5,845,508 5,845,508 5,901,714 9.74%
Div Payout % 87.55% 83.80% 99.65% 115.59% 85.66% 90.19% 79.83% -
Equity
31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 CAGR
Net Worth 83,815,975 85,785,748 83,885,667 82,869,597 83,826,660 84,436,116 83,289,500 0.42%
NOSH 11,878,513 11,878,513 11,693,337 11,693,337 11,413,994 11,241,361 11,241,361 3.74%
Ratio Analysis
31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 CAGR
NP Margin 17.48% 18.11% 16.70% 16.37% 14.21% 13.17% 14.77% -
ROE 9.25% 9.44% 9.03% 9.47% 8.14% 7.68% 8.88% -
Per Share
31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 CAGR
RPS 384.30 387.03 401.48 430.65 438.13 453.81 460.35 -11.35%
EPS 65.24 68.18 64.80 68.17 59.78 57.66 65.77 -0.53%
DPS 57.12 57.13 64.57 78.80 52.00 52.00 52.50 5.78%
NAPS 7.0561 7.2241 7.1738 7.2016 7.3442 7.5112 7.4092 -3.20%
Adjusted Per Share Value based on latest NOSH - 11,693,337
31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 CAGR
RPS 378.30 380.87 389.05 410.67 414.42 422.76 428.86 -8.02%
EPS 64.22 67.09 62.79 65.01 56.55 53.71 61.27 3.18%
DPS 56.22 56.22 62.57 75.14 48.44 48.44 48.91 9.74%
NAPS 6.9459 7.1091 6.9517 6.8675 6.9468 6.9973 6.9023 0.42%
Price Multiplier on Financial Quarter End Date
31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 CAGR
Date 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 -
Price 8.94 8.30 8.05 8.11 8.25 8.46 7.22 -
P/RPS 2.33 2.14 2.01 1.88 1.88 1.86 1.57 30.13%
P/EPS 13.70 12.17 12.42 11.90 13.80 14.67 10.98 15.91%
EY 7.30 8.21 8.05 8.41 7.25 6.82 9.11 -13.73%
DY 6.39 6.88 8.02 9.72 6.30 6.15 7.27 -8.24%
P/NAPS 1.27 1.15 1.12 1.13 1.12 1.13 0.97 19.69%
Price Multiplier on Announcement Date
31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 CAGR
Date 26/05/22 24/02/22 25/11/21 26/08/21 27/05/21 25/02/21 27/11/20 -
Price 8.98 8.70 8.11 8.45 8.33 8.09 8.29 -
P/RPS 2.34 2.25 2.02 1.96 1.90 1.78 1.80 19.13%
P/EPS 13.77 12.76 12.52 12.40 13.93 14.03 12.61 6.04%
EY 7.26 7.84 7.99 8.07 7.18 7.13 7.93 -5.72%
DY 6.36 6.57 7.96 9.33 6.24 6.43 6.33 0.31%
P/NAPS 1.27 1.20 1.13 1.17 1.13 1.08 1.12 8.74%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment